Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

MeSH terms

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / pharmacokinetics
• Antineoplastic Agents / therapeutic use*
• Benzamides
• Chronic Disease
• Dose-Response Relationship, Drug
• Female
• Follow-Up Studies
• Humans
• Hypereosinophilic Syndrome / drug therapy*
• Hypereosinophilic Syndrome / pathology
• Imatinib Mesylate
• Male
• Middle Aged
• Oncogene Proteins, Fusion / genetics
• Piperazines / administration & dosage
• Piperazines / pharmacokinetics
• Piperazines / therapeutic use*
• Pyrimidines / administration & dosage
• Pyrimidines / pharmacokinetics
• Pyrimidines / therapeutic use*
• Receptor, Platelet-Derived Growth Factor alpha / genetics
• Remission Induction / methods
• Retrospective Studies
• Splenomegaly / etiology
• Time Factors
• Young Adult
• mRNA Cleavage and Polyadenylation Factors / genetics